论文部分内容阅读
目的探讨马蔺子素(安卡)对鼻咽癌放射治疗的增敏作用及不良反应。方法158例经病理证实为鼻咽癌的患者随机分为马蔺子素联合放射治疗组(治疗组)和单纯放射治疗组(对照组),两组放射治疗方法、剂量相同,治疗组在放射治疗的同时服用安卡110mg/次,每天2次,直至放射治疗结束。采用增敏比(SER)和肿瘤的局部控制率(PR、CR)作为增敏的评价指标。根据全消率剂量曲线分析增敏效应的特征。结果鼻咽部和颈部转移病灶在达到PR和CR时的平均剂量,治疗组均明显低于对照组(P<001),增敏比为106～124,治疗结束时原发灶和颈部转移灶的CR率治疗组明显高于对照组(P<005和P<001)。当放射治疗剂量达30Gy后两组疗效开始出现差别,随着剂量的递增差别渐扩大。治疗组出现较多的恶心呕吐、腹泻等消化道反应(P<005)。照射野内正常组织未见明显增敏现象。结论马蔺子素对鼻咽癌原发灶和颈部转移灶均有明显的放射增敏作用。
Objective To investigate the sensitization and adverse reactions of melittin in radiotherapy of nasopharyngeal carcinoma. Methods One hundred and fifty-eight patients with pathologically confirmed nasopharyngeal carcinoma were randomly divided into madamemin combined with radiotherapy group (treatment group) and radiotherapy alone group (control group). The radiotherapy methods and doses of the two groups were the same. The treatment group was treated with radiation. At the same time take Anka 110mg / time, 2 times a day until the end of radiation therapy. Sensitivity ratio (SER) and tumor local control rate (PR, CR) were used as evaluation indicators for sensitization. The characteristics of sensitization effects were analyzed based on the full-rate dose curve. Results The mean doses of PR and CR in nasopharyngeal and cervical metastatic lesions were significantly lower in the treatment group than in the control group (P<001), and the sensitization ratio was 106 to 124. The primary tumor and neck were at the end of the treatment. The CR rate of metastatic lesions was significantly higher in the treatment group than in the control group (P<005 and P<001). When the dose of radiation therapy reached 30 Gy, the efficacy of the two groups began to differ, and the difference gradually increased with increasing dose. The treatment group experienced more nausea, vomiting, diarrhea and other gastrointestinal reactions (P < 005). No obvious sensitization was observed in normal tissues in the irradiated field. Conclusion Horseradish is effective in the radiosensitization of nasopharyngeal carcinoma on the primary and metastatic cervical lesions.